Skip to content

The Role of Intestinal and Vaginal Microbiota, Estrogenic Activity, Metabolic Profile & Nutritional Status in Endometriosis

UNRAVEL - The Role of Intestinal and Vaginal Microbiota, Estrogenic Activity, Metabolic Profile & Nutritional Status in Symptom Severity and Quality of Life of Portuguese Women With Endometriosis - an Exploratory Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05788952
Acronym
UNRAVEL
Enrollment
60
Registered
2023-03-29
Start date
2023-06-01
Completion date
2024-12-01
Last updated
2023-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Keywords

Endometriosis, Gut microbiota, Vaginal microbiota, Estrogenic activity, Xenoestrogens, Metabolic biomarkers, Nutritional status

Brief summary

Endometriosis (EMs) is one of the most prevalent benign gynaecological diseases, and it is an inflammatory oestrogen-dependent condition. Several authors have proposed that anatomical, genetic, endocrine, immunological, environmental, hormonal, and inflammatory factors may influence tissue implantation outside the uterus. An approach to EMs aetiology that involves defining a profile to the vaginal and gut microbiota, estrogenic activity, and exposure to xenoestrogens and also metabolic and nutritional status of women with EMs may help identify some important patterns to better characterize this disease and also to define more personalized nutritional strategies, also predicting patients' predisposition to therapy success. This is an observational study on premenopausal woman, diagnosed with EMs, who will be recruited on the outpatient gynaecology appointment, to evaluate the vaginal and intestinal microbiome, measure the total estrogenic activity, assess the metabolic biomarkers and the nutritional status.

Interventions

None listed

Sponsors

Academia CUF
CollaboratorUNKNOWN
Universidade Nova de Lisboa
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Premenopause; * Diagnose of endometriosis by clinical and/or imaging criteria (associated adenomyosis is accepted); * BMI between 18.5 and 30.0 kg/m2

Exclusion criteria

* Postmenopause; * Vegetarian diet; * Pregnancy or breastfeeding; * Continuous hormonal therapy for endometriosis; * Laparoscopic surgery for endometriosis purpose; * Gastrointestinal or vaginal infections; * Intaken antibiotics and/or probiotics within the last 8 weeks; * Medications to treat vaginal infections in the past 3 months.

Design outcomes

Primary

MeasureTime frameDescription
Omega-3 indexday 1Mean/median of omega-3 index (uL) levels at baseline.
Ascorbic acidday 1Mean/median of ascorbic acid (umol/L) levels at baseline.
Alpha (α)-tocopherolday 1Mean/median of α-tocopherol (ug/mL) levels at baseline.
Total cholesterolday 1Mean/median of total cholesterol (mg/dL) levels at baseline.
HDL cholesterolday 1Mean/median of high-density lipoprotein (HDL) cholesterol (mg/dL) levels at baseline.
LDL cholesterolday 1Mean/median of low-density lipoprotein (LDL) cholesterol (mg/dL) levels at baseline.
Insulinday 1Mean/median of insulin (μU/mL) levels at baseline.
Vaginal microbiomeday 1Characterization of the vaginal microbiome. Bacterial DNA will be extracted from cytology samples. 16S rRNA gene will be sequenced by next-generation sequencing (NGS). All the identified bacterial phyla, genus and species will be expressed in percentage.
Intestinal microbiomeday 1Characterization of the intestinal microbiome at baseline. Bacterial DNA will be extracted from fecal samples. 16S rRNA gene will be sequenced by next-generation sequencing (NGS). All the identified bacterial phyla, genus and species will be expressed in percentage.
Strogen levelsday 1Mean/median of total and free estrone (E1) and estradiol (E2) (ng E2-equivalents L-1) at baseline.
Fasting blood glucoseday 1Mean/median of fasting blood glucose levels (mg/dL) levels at baseline.
25-hydroxy vitamin Dday 1Mean/median of 25-hydroxy vitamin D (ng/mL) levels at baseline.

Secondary

MeasureTime frameDescription
Symptoms severityday 1Median of symptoms severity by the Numerical Rating Scale (NRS) at baseline. The NRS is a scale that assess pain severity at that moment in time using a 0-10 scale, with zero meaning no pain and 10 meaning the worst pain imaginable.
Quality of life questionnaireday 1Median of quality of life by the Quality of Life Scale (QOLS) questionnaire at baseline. The QOLS is a 16-item questionnaire and consists of 7 different subscales. The total score is calculated as the sum of the 16 items each ranged from 0 to 7. The final score ranges from 16 to 112 points (lower scores indicate more unfavourable conditions).

Countries

Portugal

Contacts

Primary ContactDiana Teixeira, PhD
diana.teixeira@nms.unl.pt+351218803000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026